Tag: Pd 1 inhibitor

KEYTRUDA (pembrolizumab) is an immunotherapy medicine that works with the immune system to treat certain cancers [1.3.6]. Understanding **what to expect after a KEYTRUDA infusion** is key to managing your health, from common side effects like fatigue to more serious immune-related reactions [1.2.1].

First approved by the FDA in 2014 for treating metastatic melanoma, the cancer immunotherapy drug Keytruda is one of the world's best-selling medicines. For patients and healthcare professionals, understanding which pharma company makes KEYTRUDA is important for tracing its origins and development. The answer is the pharmaceutical giant Merck & Co., Inc., also known as MSD outside the United States and Canada.

With 5-year overall survival rates for certain non-small cell lung cancer patients reaching as high as 29.6% with its use [1.10.4], it is essential to understand the answer to the question, **what class of drug is pembrolizumab?**

In non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), rilvegostomig has demonstrated an objective response rate (ORR) of 61.8% [1.5.6]. This article explores the question: What is rilvegostomig and its role in modern oncology?

According to research, mast cell tumors account for approximately 20% of all skin cancers in dogs, making them one of the most common malignancies in canines. The arrival of groundbreaking immunotherapies like **Gilvetmab** offers a new and promising approach to treating these tumors and other forms of canine cancer.